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Statins: Masked anti-epileptic warriors
Govinda Khatri a, Priya a, Ayush Kumar b, Mohammad Mehedi Hasan c, *
a

Dow University of Health Sciences, Karachi, Pakistan
Aga Khan University Hospital, Karachi, Pakistan
c
Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh
b

Statins, such as Atorvastatin and Fluvastatin, are the most frequently
prescribed medications for hypercholesterolemia. They are responsible
to inhibit the key enzyme of cholesterol biosynthesis i.e., 3-hydroxy-3methyl-glutaryl-coenzyme A reductase (HMG-CoA). HMG-CoA reduc
tase reduces HMG-CoA to Mevalonate which is an important precursor
molecule of cholesterol. Additionally, statins have a minor role as antiinflammatory and anti-oxidants [1]. It is because of these properties that
the CDC recommends the use of statin drugs for patients with a high risk
of heart attack/stroke, previous history of heart attack/stroke, high LDL
cholesterol, and occasionally diabetics [2]. However, just like most of
the routinely prescribed medications, these too come with few adverse
effects. Myopathy is the most common side effect of statins and in a few
cases, it may result in rhabdomyolysis. Hepatotoxicity, peripheral neu
ropathy, and impaired myocardial contractility are a few other un
common adverse effects that are associated with the use of statins [3].
Recently, an interesting finding has been observed in a few clinical trials
where statins have been recognized for their anti-epileptic properties
and this may be a major breakthrough in the treatment of brain insults,
that too by a widely prescribe cardiovascular drug.
A minimum of twelve published clinical cohort studies have estab
lished a strong link between the use of statins and a lower incidence of
epilepsy/seizures. These clinical cohort studies suggest that statins
lower the likelihood of developing epilepsy not just after an ischemic
stroke, but also after brain insults that occur as result of a variety of
different causes such as a brain tumor or intracranial hemorrhage [4].
One of these studies examined data from the US Department of Veterans
Affairs database for over a million people and discovered that those who
used statins had a lower likelihood of epilepsy (OR = 0.64, 95% confi
dence interval [CI] = 0.56–0.73) [5]. There are eight distinct statins in
clinical use and each has been studied for their possible
anti-epileptogenic activity. Atorvastatin, however, was the most often
used statin in the majority of clinical investigations, and it had the most

statistically significant correlation with epilepsy risk reduction [6]. The
question of whether seizures prevent or diminish the effects of statins
after discontinuation remains unanswered; however, one retrospective
clinical cohort study by Etminan M et al. attempted an analysis on this
and found no benefits for past statin users, although it had only 14 cases
in this category [7]. Several studies indicate that higher the statin use,
the stronger the ant epileptogenic impact. According to one study, those
who used statins for more than 2 weeks had a considerably reduced risk
of post-stroke epilepsy than people who took statins for less than 2 weeks
[8]. A meta-analysis conducted by Acton et al. demonstrated a statistical
association between the usage of post-stroke statins in decreasing the
incidence of early onset seizures and post-stroke epilepsy [9]. Further
more, according to a study by Marcos et al. statins are associated with
decreased mortality after status epilepticus [10]. Statin’s
anti-convulsive activity has been explained by suppressing reactive
astrogliosis with neuroinflammation during crises; stimulating
GABAergic activity while inhibiting glutamatergic; modulating the
glycogen synthase kinase-3 pathway; and decreasing monocyte infil
tration in hippocampus neuronal death and pro-inflammatory gene
expression. These lipophilic statins may readily diffuse past the blood
brain barrier and reach the central nervous system. Furthermore,
monocarboxylic acid transporters in the blood brain barrier provide an
alternate route for statins [11].
According to the recent clinical trials and studies, statins have been
shown to be more potent and widely used because they are not only
available globally but are also economically friendly. Statins are safe and
well tolerated and they have been shown to be anti-epileptogenic in a
broader variety of brain injuries than any other individual or class of
substance; and they are the only compounds with both retrospective and
prospective clinical evidence of potential anti-epileptogenic activity. To
authorize one of these statins to be used clinically for antiepilepto
genesis, its antiepileptogenic impact must be demonstrated in future
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time- and resource-intensive clinical studies. As a result, it is preferable
to conduct a study of the existing research to decide which of the statins
is the most reasonable alternative for antiepileptogenic therapy.
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